Iveric Bio Building Ophthalmology Commercial Team Ahead Of First Launch

CEO Glenn Sblendorio talked to Scrip about the company's plans to transition into a commercial-stage company after completing an NDA submission for its geographic atrophy drug in December.

building blocks — Iveric Bio is building commercially • Source: Shutterstock

Iveric Bio is building a commercial organization ahead of the potential launch of its complement C5 inhibitor avacincaptad pegol (ACP) for geographic atrophy later this year. CEO Glenn Sblendorio talked to Scrip in an interview at the J.P. Morgan Healthcare Conference in January about the firm’s transition to a commercial-stage company after finalizing a new drug application for the therapy at the end of 2022.

"Our plan has been, in the US, to launch on our own," Sblendorio said. "About a year ago, I started...